Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

Shelley Wood

December 31, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2018

Shelley Wood

July 02, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2018

Caitlin E. Cox

June 01, 2018

News Conference News ACC 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

Shelley Wood

March 27, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Features

Be It Resolved: As Evidence Mounts in Favor of a Brain-Heart Connection, Stress Should Be on the Radar During CVD Diagnosis

Yael L. Maxwell

January 16, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News Stories for 2015

Shelley Wood

December 29, 2015

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

Shelley Wood

December 29, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

Todd Neale

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Todd Neale

October 26, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Daily News

初期研究显示利伐沙班拮抗剂安全、有效

December 30, 2013

News Daily News

Rivaroxaban Antidote Appears Safe, Effective in Early Study

December 30, 2013

News Daily News

El Antídoto de Rivaroxaban parece Seguro y Eficaz en un Estudio Preliminar

December 30, 2013

News Daily News

Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin

Jason Kahn

October 04, 2013

News Daily News

Meta-analysis Suggests Vitamin C Protective Against Acute Kidney Injury

Caitlin E. Cox

September 13, 2013

News Daily News

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

L.A. McKeown

April 26, 2013

Advertisement

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

The Biggest News of 2018: TCTMD’s Top 10

TCTMD’s Top 10 Most Popular Stories for June 2018

TCTMD’s Top 10 Most Popular Stories for May 2018

My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

Be It Resolved: As Evidence Mounts in Favor of a Brain-Heart Connection, Stress Should Be on the Radar During CVD Diagnosis

TCTMD’s Top 10 Most Popular News Stories for 2015

Las 10 Noticias de TCTMD Más Leídas de 2015

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

初期研究显示利伐沙班拮抗剂安全、有效

Rivaroxaban Antidote Appears Safe, Effective in Early Study

El Antídoto de Rivaroxaban parece Seguro y Eficaz en un Estudio Preliminar

Fallout from Bleeding Less Severe in Patients on Dabigatran Compared with Warfarin

Meta-analysis Suggests Vitamin C Protective Against Acute Kidney Injury

Bivalirudin Bests Heparin for Lowering Bleeding Risk After CAS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content